Articolul precedent |
Articolul urmator |
313 8 |
Ultima descărcare din IBN: 2024-04-11 08:43 |
SM ISO690:2012 CARACAŞ, Anastasia, VASILACHE, Eugenia, CHIANU, Marin, ȘTÎRBA, Dumitru, BACHINSKY, N.G.. Use of antimycotics in patients hospitalized with COVID-19. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 32. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 32-32 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Candida species are responsible for most superficial and disseminated fungal infections in humans. Recent epidemiological studies indicate an increase in the resistance of Candida species to azoles, which is a problem of critical importance in the clinical setting. Objective of the study. Identification of antifungal drugs prescribed for prophylactic purposes in patients hospitalized with Covid-19, exposed to antibacterial treatment. The evaluation of the rationality of administration and determination of alternative therapies. Material and Methods. 100 medical prescription sheets of patients with Covid-19 hospitalized in the reprofiled sections of the MCH „Gheorghe Paladi” were selected and analyzed to identify the antifungal drugs administered. The literature review was performed to elucidate the rationality of administration and for evaluation of the antifungal effects of probiotics. Results. 100 patients received antifungal drugs, including-only fluconazole-86, and in combination with nystatin - 14 patients. The administration of probiotics (linex, subtyl) was identified in 9 patients. All patients hospitalized with Covid-19 who administered antifungals received concomitant antibacterial therapy with preparations from various groups (cephalosporins, fluoroquinolones, penicillins, macrolides, etc.). Candida susceptibility to antifungal preparations was determined in only 5 patients and demonstrated resistance to the azole group (itraconazole, fluconazole, clotrimazole) and sensitivity to amphotericin B and nystatin. Conclusion. Fluconazole is the most prescribed antifungal, but the increased resistance to the azole group of Candida requires a review of the prescription of antifungals for prophylactic purposes. The necessity to associate nystatin as well as the use of probiotics with beneficial effects was noted. |
||||||
Cuvinte-cheie Candida, antifungals, resistence, probiotics, COVID-19, Candida, antimicotice, rezistenţă, Probiotice, COVID-19 |
||||||
|